GlassScriptPhysician profile
Stephen Q Montgomery
NPI 1699735159
$1,841.33
in general payments reported to CMS, 2019-2025
22 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $228 · 2021: $235 · 2022: $197 · 2023: $302 · 2024: $194 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $343.41 | 2019-2025 | Evenity, Prolia, Prolia |
| Otsuka America Pharmaceutical, INC. | $228.78 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $163.13 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $160.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.87 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $125.19 | 2019-2021 | |
| Abbvie INC. | $117.25 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $105.73 | 2019-2023 | Eliquis, Camzyos |
| Lilly USA, LLC | $91.41 | 2019-2025 | Kisunla, Mounjaro, Trulicity |
| Lundbeck LLC | $78.54 | 2024-2025 | Rexulti |
| Shield Therapeutics INC | $50.31 | 2023-2024 | Accrufer |
| Amarin Pharma, INC. | $49.96 | 2020 | |
| Glaxosmithkline, LLC. | $41.35 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $26.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.24 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.29 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.19 | 2021 | |
| Nevro Corp. | $17.60 | 2023 | Senza |
| Avanir Pharmaceuticals, INC. | $14.04 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.88 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.85 | 2022 | |
| Sumitomo Pharma America, INC. | $5.00 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.